Amarin's (AMRN 1.15%) share price took a hit this month after the Food and Drug Administration announced that it has still not decided whether the company's flagship drug, Vascepa, qualifies for New Chemical Entity, or NCE, status. Shares of Amarin are up today, however, on news that two new patents have been approved for Vascepa.
Although patents are an essential long-term shield against generic competition, will this really move the needle for Amarin's stock in the short term? Is NCE status still the biggest catalyst that investors need to watch?
In the following video, health care analysts Max Macaluso and Brenton Flynn discuss these issues.
